FORM 10-K

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


          [X]  ANNUAL REPORT PURSUANT  TO SECTION 13  OR 15(d) OF  THE
               SECURITIES EXCHANGE ACT OF 1934 [FEE REQUIRED]

                            for the fiscal year ended
                               September 30, 1997

                                       or

          [  ] TRANSITION REPORT  PURSUANT TO  SECTION 13 OR  15(d) OF
               THE SECURITIES EXCHANGE ACT OF 1934 [NO FEE REQUIRED]

                                     1-12318
                             Commission file number

                            BALLARD MEDICAL PRODUCTS
                            Exact name of registrant 
                           as specified in its charter

                                      UTAH
                  State or other jurisdiction of incorporation 
                                 or organization

                                   87-0340144
                       I.R.S. Employer Identification No.  
                  
                 12050 Lone Peak Parkway, Draper, Utah  84020  
                              Address and Zip Code 
                         of principal executive offices

                                 (801) 572-6800
                         Registrant's telephone number, 
                              including area code 


          Securities registered to 12(b) of the Act:  None

          Securities registered pursuant to Section 12(g) of the Act: 

                           Title of Class:  Common   
                           Par Value:  $0.10 per share

          [X]  Yes  Indicate by check mark whether the Registrant (1)
          [ ]  No   has  filed all  reports  required to  be filed  by
                    Section 12 or 15(d) of the Securities Exchange Act
                    of  1934 during  the preceding  12 months  (or for
                    such  shorter  period  that  the   registrant  was  
                    required to  file such reports), and  (2) has been
                    subject to  such filing requirements  for the past
                    90 days.    

          [ ]       Indicate by check mark if disclosure of delinquent
                    filers  pursuant  to  Item 405  of  Regulation S-K
                    (Section 229.405 of this chapter) is not contained
                    herein, and will not be  contained, to the best of
                    registrant's  knowledge,  in  definitive proxy  or
                    information  statements incorporated  by reference
                    in  Part III of this Form 10-K or any amendment to
                    this Form 10-K.  

          The  aggregate market  value  of the  voting  stock held  by
          nonaffiliates of the registrant as of 12/11/97: 

                                  $636,534,779

          The number  of shares outstanding of  the registrant's class
          of common stock, as of 12/11/97:

                                   29,030,983

                       DOCUMENTS INCORPORATED BY REFERENCE

          The  following  documents   are  incorporated  by  reference
          herein:

                1.  Annual  Report  to  Shareholders for  fiscal  year
                    ended September 30, 1997:  Incorporated into Parts
                    I and II hereof.
            
                2.  Proxy Statement for Annual Meeting of Shareholders
                    to be  held January  26, 1998:   Incorporated into
                    Part III hereof.


                            BALLARD MEDICAL PRODUCTS

                     Cross Reference Sheet Showing Location 
                      in Annual Report or Proxy Statement 
               of Information Required by Certain Form 10-K Items


                                                               LOCATION IN
           FORM 10-K ITEMS                                     REFERENCE
                                                               MATERIALS


           Part I

                Item 1.      Business                          Annual Report,
                                                               pp. 1-8   

                Item 2.      Properties                        Annual Report,
                                                               pp. 1,2

           Part II.

                Item 5.      Market for Registrant's Common    Annual Report p.
                             Equity and Related Stockholder    8
                             Matters

                Item 6.      Selected Consolidated Financial   Annual Report,
                             Data                              pp. 7-8

                Item 7.      Management's Discussion and
                             Analysis of Financial Condition   Annual Report,
                             and Results of Operations         pp. 26-33

                Item 8.      Consolidated Financial
                             Statements and Supplementary      Annual Report,
                             Data                              pp. 10-25

           Part III

                Item 10.     Directors and Executive             
                             Officers of the Registrant        Proxy Statement,
                                                               pp. 3,4, 16-19

                Item 11.     Executive Compensation            Proxy Statement,
                                                               pp. 5-11

                Item 12.     Security Ownership of Certain
                             Beneficial Owners and             Proxy Statement,
                             Management                        pp. 3-4


                                   DEFINITIONS

          As  used  herein,  the  following terms  have  the  meanings
          indicated:

                1.  "Annual  Report"  refers to  the  Company's Annual
                    Report  for the  fiscal year  ended September  30,
                    1997, which was EDGAR-filed with the Commission on
                    or about December 12, 1997 and which was mailed to
                    shareholders on or about December 12, 1997.

                2.  "Ballard" refers to Ballard Medical Products.

                3.  "BI"  refers  to  Ballard  International,  Inc., a
                    wholly-owned subsidiary of Ballard.

                4.  "BREH" refers  to  Ballard Real  Estate  Holdings,
                    Inc., a wholly-owned subsidiary of Ballard.

                5.  "Cardiotronics"  refers to  Cardiotronics Systems,
                    Inc., a wholly-owned subsidiary of Ballard.

                6.  The  "Company"  and  the  "Registrant"   refer  to  
                    Ballard and its subsidiaries.

                7.  "MIC" refers to Medical Innovations Corporation, a
                    wholly-owned subsidiary of Ballard.

                8.  "MIST  ASSIST" refers  to  Mist  Assist,  Inc.,  a
                    wholly-owned subsidiary of Ballard.

                9.  "PEPCO" refers to the Plastic  Engineered Products
                    Company, a wholly-owned subsidiary of Ballard.

               10.  "PMP" refers to Ballard Medical  Products (Canada)
                    Inc.  dba  Preferred Medical  Products,  a wholly-
                    owned subsidiary of Ballard.

               11.  The  "Proxy Statement"  refers  to  the  Company's
                    Proxy  Statement which  was  EDGAR-filed with  the
                    Commission on or about December 12, 1997 and which
                    was mailed to  shareholders on  or about  December
                    12, 1997, for the Annual Shareholder Meeting to be
                    held January 26, 1998.

               12.  "R2" refers to R2 Medical Systems, Inc., a wholly-
                    owned subsidiary of Cardiotronics.


                                     PART I

          ITEM 1.  BUSINESS

               The information  required by this  item is incorporated
          herein by reference  from the Company's  Annual Report.   In
          addition, the following information is provided:

               BUSINESS DEVELOPMENTS

               The United States continues  to be the principal market
          for the Company's products.   The Company's 145-person sales
          force is complemented by  a distribution system comprised of
          specialty and general line dealers.

               Sales by the Company are generated in many areas within
          the  hospital,  such  as  intensive  care  units,  emergency
          services, anesthesiology  departments, oncology departments,
          pain  clinics,  gastrointestinal  and   radiology  procedure
          rooms,   burn  units,   respiratory  therapy,   bone  marrow
          transplant   units,  general   nursing  floors,   and  post-
          anesthesia  care  units,  as   well  as  the  main  hospital
          operating room and outpatient/satellite surgical centers.  A
          second  important  market  for  certain  of   the  Company's
          products is the alternate care market.  Alternate  care site
          sales continue to  improve as patients are moved  into these
          locations at an increasing rate.  

               The  sale  of  the  Company's TRACH  CARE  products  is
          somewhat  seasonal,  in that  sales  are  better during  the  
          winter  months   when  there  is  a   greater  incidence  of
          respiratory illness.  Other product sales are not subject to
          seasonal differences.

               INDUSTRY SEGMENTS

               All products of  the Company  are deemed to  be of  the
          same class and are sold in the same industry segment.

               RAW MATERIALS

               The Company  does not face any  serious supply shortage
          with respect to raw materials used in the manufacture of its
          products.   Many of the Company's  products are manufactured
          from  various resins  and plastics.   The  Company purchases
          resins  and plastics  from  a number  of different  vendors.
          Resin availability is adequate for our needs. 

               The Company's  Chlorhexidinegluconate ("CHG") solutions
          used  in  its  FOAM CARE  products  are  purchased  from two
          different suppliers.  The 4% CHG is currently purchased from
          Xttrium  Laboratories, Inc.,  and  the 2%  CHG is  currently
          purchased from  Huntington Laboratories, Inc.   The  Company
          has written  supply contracts  with Xttrium  and Huntington.
          However,  there can be no assurance that the Company will be
          able to continue to have  access to sufficient quantities of
          these CHG materials.  CHG is heavily regulated by the FDA.  

               The  Company  purchases  significant amounts  of  paper
          products, along with a number of different chemicals used in
          the manufacture of other hand wash solutions sold as part of
          the Company's  FOAM  CARE  product  line.   There  are  many
          different suppliers of  such chemicals  and paper  products.
          Occasionally, paper product companies  are in short  supply,
          but  the Company  has  adjusted lead  times  and made  other
          adjustments  so  that  this  has  not  presented  a  serious
          problem.

               The Company  used to  purchase  substantial amounts  of
          tubing from outside sources.  Now  the Company extrudes most
          of its own tubing.

               The Company also purchases  different types of silicone
          materials  from  various  suppliers.    Depending  upon  the
          specific type of silicone  involved, there are anywhere from
          a  few to many sources.  Some manufacturers have scaled back
          their supply  of silicone  materials which are  implanted or
          placed in the human body for  more than thirty days, in part
          because   of  legal  problems  surrounding  silicone  breast
          implants.    So far,  the Company  has  not had  any serious
          difficulty obtaining needed silicone materials.

               There are many  potential sources of  balloon materials
          used by the Company in the MIC enteral feeding product line,  
          although the Company  currently purchases substantially  all
          of such balloons from one source.

               There  are  multiple vendors  of  needles and  syringes
          needed for PMP products, and foam needed for PEPCO products.
          The  Company  has  encountered  supply   problems  regarding
          needles, which are purchased from various vendors, including
          some international  suppliers.   Long lead  times (up  to 18
          weeks sometimes)  are required  for the ordering  of certain
          needles.

               PATENTS

               The Company  owns numerous patents with  respect to its
          products  and   feels  that  these  patents   are  extremely
          important to the Company's ability to compete effectively in
          the market place.

               1.  TRACH CARE

               The Company  owns 24 U.S.  patents with respect  to its
          TRACH  CARE  family of  products.   The expiration  dates on
          these patents  range from  February, 2003 to  January, 2014.
          The  Company  also  has  several U.S.  and  foreign  patents
          pending covering various TRACH CARE improvements.

               2.  MIC 

               The MIC  family of  products (including  products added
          from  the   April,  1996   acquisition  of  the   assets  of
          Endovations, Inc.) are protected by 31 U.S. patents owned by
          the  Company, along with various foreign  patents.  The U.S.
          patents  expire  between January,  1999 and  November, 2014.
          The Company also  has other U.S. and foreign patents pending
          on  MIC products,  and  is a  licensee  of certain  patented
          technology under license agreements.

               3.  FOAM CARE

               The Company's  FOAM CARE  products are protected  by 11
          U.S. patents either owned or licensed by the  Company, along
          with  a  number of  foreign  patents.    The Company's  U.S.
          patents  expire between  July 2002  and August,  2011.   The
          Company  also has  other U.S.  and foreign  patents pending,
          covering its FOAM CARE technology.

               4.  EASI-LAV

               The Company owns  6 U.S.  patents with  respect to  its
          EASI-LAV products, with expiration  dates ranging from June,
          2006 to July, 2014.   There are also other  pending U.S. and
          foreign patents.

          TRADEMARKS  

               1.  BALLARD TRADEMARKS

               Although  patents  and  registered  trademarks  do  not
          provide  guaranteed  protection, the  Company  believes that
          they are important to its competitive position in the health
          care marketplace.  The Company's rights in a given trademark
          should last  indefinitely, so long as  the Company continues
          to use the mark to identify the particular product involved.
          Ballard  owns numerous  trademarks, including  the following
          which have been registered in the U.S. Patent and  Trademark
          Office:

               REGISTRATION   REGISTRATION        REGISTERED
               NUMBER         DATE                TRADEMARK

               1,987,599      July 16, 1996       TRACH CARE MAC
               1,970,481      April 23, 1996      MIST ASSIST
               1,840,243      June 21, 1994       FOAM CARE
               1,837,691      May 31, 1994        FLASH FOAM
               1,818,717      February 1, 1994    CHAR-FLO
               1,797,703      October 12, 1993    CODE BLUE EASI-LAV
               1,793,553      September 21, 1993  BAL-CATH
               1,757,543      March 9, 1993       DENTASWAB POLY-PLUS
               1,753,765      February 23, 1993   BALLARD UNIT DOSE
               1,690,024      June 2, 1992        ENDO-GUARD
               1,662,948      October 29, 1991    PEPCO
               1,655,483      September 3, 1991   EASI-LAV
               1,639,354      March 26, 1991      JAW-BLOCKER
               1,608,110      July 31, 1990       TRACH CARE WET PAK
               1,569,479      December 5, 1989    SAFETY DRAIN
               1,509,875      October 25, 1988    DENTASWAB
               1,500,402      August 16, 1988     READY CARE
               1,491,006      June 7, 1988        SAFETY SHIELD KIT
               1,403,724      August 5, 1986      ENDOCAINE
               1,358,802      September 10, 1985  FOAM CARE
               1,358,803      September 10, 1985  FOAM CARE (stylized)
               1,338,744      June 4, 1985        BALLARD MEDICAL PRODUCTS
               1,330,753      April 16, 1985      ENDO-GUARD with design
               1,328,358      April 2, 1985       TRACH CARE
               1,328,357      April 2, 1985       DOUBLE SCRUB
               1,325,596      March 19, 1985      FOAM CARE DOUBLE SCRUB
               1,286,773      July 24, 1984       XYLO-TOL
               1,277,803      May 15, 1984        LAC-TOL
               1,274,743      April 24, 1984      QUIK-PREP
               1,225,871      February 1, 1983    R2

               2.  MIC TRADEMARKS

               MIC  has registered the  following trademarks  with the
          United States  Patent and  Trademark Office, in  addition to
          others pending:

               REGISTRATION   REGISTRATION        REGISTERED
               NUMBER         DATE                TRADEMARK  

               2,036,645      February 11, 1997   BASICS
               2,004,268      October 1, 1996     LARIAT
               1,912,396      August 15, 1995     THERMAL OPTION 
               1,897,441      June 6, 1995        WE MAKE LIFE A LITTLE EASIER
               1,853,026      September 6, 1994   CAN-OPT
               1,746,978      January 19, 1993    SHUR-FORM
               1,713,379      September 8, 1992   MIC-KEY
               1,607,979      July 31, 1990       ENDOVATIONS
               1,548,136      July 18, 1989       MEDICAL INNOVATIONS
                                                  CORPORATION (with Snakes)
               1,512,575      November 15, 1988   SECUR-LOK
               1,414,121      October 21, 1986    MIC (with Snakes)

               The   Company   also   maintains    foreign   trademark
          registrations  in various  foreign countries  and has  other
          trademark registrations pending.

               MANUFACTURING BACKLOG

               Generally, all sales of  product by the Company include
          terms  requiring payment  within  thirty days.   Product  is
          typically  not allowed  to be  returned unless  defective or
          shipped in error.  As of November 17, 1997, the Company  had
          back orders (believed to be firm) of approximately $219,279,
          in contrast to  approximately $159,155 in back orders at the
          same  time in 1996.  Back orders are generally filled within
          ten days.  Most of these back orders are custom kits.

               COMPETITION

               Each  of  the  Company's  products  competes  in  major
          markets within  the  health  care  industry.   Many  of  the
          Company's competitors are larger and more established in the
          market  place than  the Company,  and many  competitors have
          larger  research staffs,  facilities, and  marketing forces.
          However, the  aggressive marketing  and unique  qualities of
          the Company's product lines continue to be well received and
          are  helping  the  Company  maintain,  and  in  some  cases,
          increase its  portion of the  market.  The  Company's market
          share and competition  vary from  product to  product.   The
          Company  estimates there  are approximately  ten  to fifteen
          competing  companies for  its FOAM  CARE products,  three or
          four competitors for  its TRACH CARE  products, and four  or
          five  competitors   for  its  Cardiotronics   product  line.
          Depending upon the specific product line, there are anywhere
          from  no competitors  to three or  four competitors  for MIC
          products.   Each year,  there are  an  increasing number  of
          competitors for each of these product lines.  

               EMPLOYEES 

               The  Company currently  has 1,145  full-time employees,
          782 of whom are hourly production employees.  The total U.S.
          and  foreign sales force now numbers 145, split into a TRACH  
          CARE/CARDIO/R2   sales   force   with  44   representatives,
          MIC/ENDOVATIONS/COX sales force  with 48 representative, and
          a PMP/FOAM  CARE sales  force with  26 representatives.   In
          addition, there are 14 full-time division and national sales
          managers,  3  sales  trainers,  and 10  international  sales
          representatives and 1 director of international sales.  

               MANUFACTURING AND WORKING CAPITAL

               All  of  Ballard's  products are  assembled,  and  many
          component parts are manufactured, at the Company's premises,
          located in Draper, Utah  and Pocatello, Idaho, where Ballard
          has complete  facilities for the design  and construction of
          the  Company's own tooling,  prototype molds, and production
          molds.  Cardiotronics' products  are manufactured at a plant
          in Carlsbad,  California.  However, this  operation is being
          moved  to Pocatello within the  next couple of  months.  The
          Company   uses  plastic   injection  molding   and  assembly
          techniques in the manufacture of many of its products.  

               RESEARCH AND DEVELOPMENT

               The  Company maintains  a  staff of  design  engineers,
          project   managers,  and  other   employees  for  continuing
          research  and development of products.   We are committed to
          constantly searching for  new products and for  improvements
          to  existing products,  and we  are committed  to allocating
          sufficient  resources  to meet  these  important objectives.
          The following table sets  forth the amounts expended by  the
          Company  in  the  last   three  fiscal  years  for  Company-
          sponsored, in-house research and development activities:

                                        9/30/97      9/30/96     9/30/95

           Company-sponsored 
           in-house research and
           development expenses      $2,735,298   $2,903,805  $2,177,117

          ITEM 2.  PROPERTIES

               Information  required  by  this  item  is  incorporated
          herein by  reference from the  Company's Annual Report.   In
          addition, the following information is provided:

               The  Company   owns  a  378,000  square-foot  plant  on
          approximately  twenty acres  of  land in  Draper, Salt  Lake
          County, Utah.   This  facility includes a  separate finished
          goods warehouse (102,000 square feet) which was completed in
          August,  1997  at  a   construction  cost  of  approximately
          $3,367,000.

               The  Company  also  owns   a  manufacturing  plant   in
          Pocatello,   Idaho   (208,000   square   feet),   of   which  
          approximately  104,000   square  feet  were  added   on  and
          completed  in April,  1997  at a  cost  of approximately  $5
          million.

               On April  29, 1997,  the Company sold  approximately 61
          acres  of BREH's real estate (located south of the Company's
          Draper  plant)  for  approximately  $3,266,000  cash  and  a
          $3,974,000 note.  The note provides, among other things, for
          interest at 8.0%, for payment of all accrued interest in one
          year and for payment in full of all accrued interest and the
          entire  principal balance in two years.  The note is secured
          by  a first trust deed against approximately 42 acres of the
          property sold and certain related water shares.

               On  August 29, 1997 the  Company sold the  6.5 acres it
          acquired in 1996  in Fremont, California at a purchase price
          of $2,326,000.

               MIC   closed  its  Milpitas,  California  facility  and
          terminated the building lease  effective July 31, 1997, with
          terms  which  included  a  $44,000  early cancellation  fee.
          MIC's  manufacturing  operations  are  now  located  at  our
          Pocatello, Idaho plant. 

               We  estimate,  given  the  current  product  mix  being
          manufactured in Pocatello, the  existing plant has a current
          single-shift volume of approximately  $13 millon.  After the
          MIC operations are relocated  to Pocatello, we estimate that
          the  plant will  then have  a capacity of  approximately $30
          million to $40 millon.

               In  August,  1996,  the  Company  acquired,  indirectly
          through  a Canadian subsidiary, a small building (on 2 acres
          of  land)  in  Thorold, Canada,  at  a  total  cost of  U.S.
          $886,069.  This real estate purchase was made in conjunction
          with the acquisition  of PMP.   We are  currently seeking  a
          tenant for this facility.

          ITEM 3.  LEGAL PROCEEDINGS

               R2 MEDICAL SYSTEMS, INC. AND CARDIOTRONICS SYSTEMS,
               INC. v. KATECHO, INC., CARDIOVASCULAR GROUP OF OREGON,
               INC., AND PADECO, INC.

               R2  and  Cardiotronics  were  plaintiffs  in  a  patent
          infringement lawsuit against  Katecho, Inc.,  Cardiovascular
          Group of Oregon, Inc.  and Padeco, Inc.  filed in the United
          States District Court for  the Northern District of Illinois
          Eastern Division as Case No. 94C3131.  A jury trial was held
          during the week of November 3, 1997.  On November  10, 1997,
          the  jury returned a verdict finding that the Katecho device
          does not infringe the  patents of R2 and Cardiotronics.   On
          or about December 3, 1997, R2 filed a motion for a new trial
          which claims  that  the jury  verdict  was contrary  to  the 
          evidence and that the court allowed evidence to be  admitted
          which, R2  believes, improperly influenced the jury.  In the
          alternative, the motion  asks the court to  enter a judgment
          finding infringement.

               J. MICHAEL KRAMER V. R2 MEDICAL SYSTEMS, ET AL.

               R2 is a co-defendant  in this ongoing product liability
          case filed  in the Supreme Court  of the State of  New York,
          County of Suffolk, as Case No. 01787/94.  This case is still
          in the discovery phase, and settlement discussions are being
          pursued.

               ROGER LEE HEATH v. BAXTER, WALTERS, TOWNSEN, ET AL.

               On or  about March  18, 1997,  the court dismissed  Mr.
          Heath's lawsuit  with prejudice (which means  that he cannot
          refile the complaint in the United States District Court).

               Mr.  Heath has  appealed the  court's dismissal  to the
          United  States Court of Appeals  for the 7th  Circuit.  This
          appeal is still pending.

               OTHER LITIGATION

               The  Company  is  also  a  party  to  ordinary  routine
          litigation  (including  other product  liability litigation)
          incidental to the Company's business.

          ITEM 4.   SUBMISSION  OF  MATTERS  TO  A  VOTE  OF  SECURITY
                    HOLDERS

               During  the fourth  quarter  of the  fiscal year  ended
          September 30, 1997, no  matters were submitted to a  vote of
          shareholders.


                           FORWARD-LOOKING STATEMENTS

               From time to  time the Company may  report, through its
          press releases, its Annual  Report, and SEC filings, certain
          matters  that  could  be  characterized  as  forward-looking
          statements subject  to  risks and  uncertainties that  could
          cause  actual  results  to   differ  materially  from  those
          projected.  Such risks  and uncertainties may include, among
          other    things,   economic,    competitive,   governmental,
          technological,  and other factors discussed in the Company's
          filings with the  SEC on  Forms 10-K, 10-Q,  and 8-K.   Such
          forward-looking  statements are  made pursuant  to  the safe
          harbor  provisions  of  the  Private  Securities  Litigation
          Reform Act of 1995.


                                  RISK FACTORS

               Forward-looking  statements are, of  course, subject to  
          risks and  uncertainties that could cause  actual results to
          differ  materially from  those  projected.   Such risks  and
          uncertainties may include, among other things, the following
          items, certain of which are beyond management's control.

               COMPETITION.      The   medical   device   industry  is
          characterized by rapidly  evolving technology and  increased
          competition.  There are a number of companies that currently
          offer,  or are in  the process of  developing, products that
          compete with products offered by the Company.  Some of these
          competitors  have  substantially greater  capital resources,
          research  and  development  staffs  and  experience  in  the
          medical device  industry.  These competitors  may succeed in
          developing technologies and products that are more effective
          than those currently used or produced by the Company or that
          would render  some products offered by  the Company obsolete
          or noncompetitive.   Competition based on  price is becoming
          an  increasingly  important  factor  in  customer purchasing
          patterns as  a result of cost containment  pressures on, and
          consolidation   in,  the   health  care   industry.     Such
          competition has exerted, and is likely to continue to exert,
          downward  pressure  on the  prices  the Company  is  able to
          charge  for its products.   The Company  may not be  able to
          offset  such downward  price pressure  through corresponding
          cost  reductions.   Price reductions  could have  an adverse
          impact on  the business, results of  operations or financial
          condition of the Company. 

               INTELLECTUAL PROPERTY  RIGHTS.  From time  to time, the
          Company has received, and in the future may receive, notices
          of  claims  with respect  to  possible  infringement of  the
          intellectual   property  rights  of  others  or  notices  of
          challenges  to the  Company's intellectual  property rights.
          In some instances such notices have given rise to, or may in
          the  future  give  rise  to,  litigation.    Any  litigation
          involving the  intellectual property  rights of  the Company
          may  be resolved by means  of a negotiated  settlement or by
          contesting the  claim through  the judicial process.   There
          can be no assurance that the business, results of operations
          or the financial condition of the Company will not suffer an
          adverse impact  as a result of  intellectual property claims
          that may  be commenced  against the Company  in the  future.
          The Company owns certain patents and proprietary information
          acquired   while   developing   its  products   or   through
          acquisitions,  and the  Company is  the licensee  of certain
          other   technology.    As  patents  expire,  more  competing
          products  may  be released  into  the  marketplace by  other
          companies.    The ability  of  the  Company to  continue  to
          compete effectively with other medical device  companies may
          be materially dependent upon  the protection afforded by its
          patents  and  the  confidentiality  of  certain  proprietary
          information.  There can be no assurance that patents will be
          issued  for  products   and  product  improvements  recently
          released  into  the marketplace  or  for  products presently  
          being developed.

               MANAGED   CARE   AND   OTHER   HEALTH   CARE   PROVIDER
          ORGANIZATIONS.  Managed care  and other health care provider
          organizations  have  grown  substantially  in terms  of  the
          percentage  of  the population  in  the  United States  that
          receives medical benefits through such organizations  and in
          terms of the  influence and  control that they  are able  to
          exert over an increasingly large portion of  the health care
          industry.  These organizations are continuing to consolidate
          and grow,  increasing the ability of  these organizations to
          influence the practices and pricing involved in the purchase
          of  medical  devices, including  the  products  sold by  the
          Company.

               HEALTH CARE  REFORM/PRICING PRESSURE.   The health care
          industry  in  the  United  States  continues  to  experience
          change.   Health care reform proposals  have been formulated
          by  members of  Congress.   In addition,  state legislatures
          periodically consider various  health care reform proposals.
          Federal, state and local government representatives will, in
          all likelihood,  continue to  review and  assess alternative
          health care delivery systems and payment methodologies,  and
          ongoing public debate of these issues can be expected.  Cost
          containment  initiatives,  market  pressures   and  proposed
          changes  in  applicable  laws  and regulations  may  have  a
          dramatic effect  on pricing or potential  demand for medical
          devices,  the relative costs  associated with doing business
          and  the  amount of  reimbursement  by  both government  and
          third-party  payors.     In  particular,   the  industry  is
          experiencing  market-driven reforms  from forces  within the
          industry that are exerting pressure on health care companies
          to reduce  health care  costs.  These  market-driven reforms
          are  resulting  in   industry-wide  consolidation  that   is
          expected  to  increase  the  downward  pressure  on  product
          margins, as  larger buyer and supplier  groups exert pricing
          pressure on  providers of  medical devices and  other health
          care  products.     Both   short-term  and   long-term  cost
          containment   pressures,  as  well  as  the  possibility  of
          regulatory  reform,  may  have  an  adverse  impact  on  the
          Company's  results of  operations  and financial  condition.
          The  Company's  products  consist  primarily  of  disposable
          medical devices.   Cost  containment pressures  on hospitals
          are  leading  some  facilities  to  use  certain  disposable
          devices  longer than they have  been used in  the past, even
          longer than permitted by product labelling.  This phenomenon
          could  result  in  a  reduction in  Company  sales,  because
          extended use and device reuse mean fewer unit purchases.

               GOVERNMENT  REGULATION.   There  has  been  a trend  in
          recent  years, both  in the  United  States and  outside the
          United  States, toward  more  stringent  regulation of,  and
          enforcement  of requirements  applicable to,  medical device
          manufacturers.    The  continuing  trend of  more  stringent 
          regulatory  oversight in  product clearance  and enforcement
          activities  has  caused   medical  device  manufacturers  to
          experience longer approval cycles, more uncertainty, greater
          risk and greater expense.  At the present time, there are no
          meaningful indications that this trend  will be discontinued
          in the  near-term  or the  long-term  either in  the  United
          States  or abroad.  The Company expects to continue to incur
          additional  operating expenses  associated with  its ongoing
          regulatory  compliance  program,  but  the  amount  of these
          incremental costs  cannot be  completely predicted  and will
          depend upon  a variety of factors,  including future changes
          in   statutes  and  regulations   governing  medical  device
          manufacturers.    There  can   be  no  assurance  that  such
          compliance requirements and  quality assurance programs will
          not have  an  adverse impact  on  the business,  results  of
          operations or financial condition of the Company or that the
          Company  will not  experience problems  associated with  FDA
          regulatory compliance.

               NEW PRODUCT INTRODUCTIONS.  As the existing products of
          the Company become more mature and its existing markets more
          saturated,  the importance  of developing  or acquiring  new
          products  will  increase.    The  development  of  any  such
          products   will  entail   considerable  time   and  expense,
          including research  and development  costs and the  time and
          expense required  to obtain necessary  regulatory approvals,
          which  could  adversely  affect  the  business,  results  of
          operations or financial condition of the Company.  There can
          be no assurance that  such development activities will yield
          products that can be  commercialized profitably, or that any
          product  acquisition  can  be  consummated  on  commercially
          reasonable  terms  or at  all.   Any  failure to  acquire or
          develop  new  products to  supplement  more  mature products
          could have  an adverse  impact on  the business, results  of
          operations or financial condition of the Company.

               TECHNOLOGICAL   CHANGE.    The  medical  technology  as
          utilized by  the Company has been subject to rapid advances.
          While  the Company  feels  that it  currently possesses  the
          technology  necessary  to   carry  on   its  business,   its
          commercial  success will  depend  on its  ability to  remain
          current with  respect to such technological  advances and to
          retain  experienced technical personnel.  Furthermore, there
          can be  no assurance that other  technological advances will
          not  render the  Company's technology  and certain  products
          uneconomical or obsolete.

               PRODUCT LIABILITY EXPOSURE.   Because its products  are
          intended  to be used in health care settings on patients who
          are physiologically  unstable and  may also be  seriously or
          critically ill, the Company  is exposed to potential product
          liability claims.   From  time to  time, patients using  the
          Company's  products have  suffered serious injury  or death,
          which  has  led  to  product liability  claims  against  the  
          Company.  Some product  liability claims have been inherited
          by the  Company through business acquisitions.   The Company
          does not believe  that any of these  claims, individually or
          in the aggregate, will have a material adverse impact on its
          business,  results  of  operations or  financial  condition.
          However, see Item 1.  "Legal Proceedings."  Furthermore, the
          Company may, in  the future, be subject to product liability
          claims that could have such an adverse impact.

               The  Company  maintains product  liability  coverage in
          amounts that it deems sufficient for its business.  However,
          there can be no assurance that such coverage will ultimately
          prove to be adequate, or that such coverage will continue to
          remain available on acceptable terms or any terms at all.

               ACQUISITIONS.   In order to  continue increasing  sales
          volume and profits, the Company  relies heavily on a program
          of  acquiring  business and  new  product  lines from  other
          companies.   There is always a significant risk that a given
          acquisition by  the Company will prove to be unsuccessful or
          end  up not  contributing sufficiently  to sales  and profit
          growth   of  the  Company.    There  is  also  a  risk  that
          undiscovered  or  contingent   liabilities  of  an  acquired
          company  could  negatively  impact  the  Company's financial
          position or  even the  acquisition transaction itself.   The
          integration of any businesses that the Company might acquire
          could require  substantial management resources.  The moving
          of acquired  product lines can also  result in interruptions
          in  production and  backorders.   There can be  no assurance
          that  any  such  integration  will  be  accomplished without
          having a  short or  potentially long-term adverse  impact on
          the business, results  of operations or  financial condition
          of the Company or  that the benefits expected from  any such
          integration will be fully realized.

               LACK  OF  DIVIDENDS.     Prior  to  January,  1990,  no
          dividends  had been  paid by  the Company  on its  shares of
          Common Stock.  The Company has paid dividends since January,
          1990.   However, there  can be  no assurance  that dividends
          will be paid on shares in the future, particularly since the
          Company prefers  to reserve its  cash and liquid  assets for
          growth and possible business acquisitions.

               UNCERTAINTY  OF FINANCIAL  RESULTS  AND CAPITAL  NEEDS.
          There  may  be  substantial fluctuations  in  the  Company's
          results of operations because of the timing and recording of
          revenues and market acceptance of existing Company products.
          The ability of  the Company to expand  its manufacturing and
          marketing operations cannot be predicted with certainty.  If
          revenues do not continue to increase as rapidly as they have
          in  the past few  years, or if  manufacturing, marketing, or
          research and development are  not successful or require more
          money than  is anticipated,  the Company  may have  to scale
          back  product marketing, development  and production efforts 
          and attempt to obtain  external financing.  There can  be no
          assurance that  the Company would  be able to  obtain timely
          external  financing in  the  amounts required  or that  such
          financing, if  available, would be on  terms advantageous to
          the Company. 

               SUPPLY  OF RAW  MATERIALS.   Certain  of the  Company's
          products are  dependent upon  raw materials for  which there
          are single  or few sources.  So far, the Company has not had
          any  serious  problems   obtaining  needed  raw   materials.
          However,  there can be no assurance that the Company will be
          able to  continue to depend  on existing sources  of certain
          materials. 

               IMPACT OF CURRENCY FLUCTUATIONS; IMPORTANCE  OF FOREIGN
          SALES.   Because certain  sales of  products by the  Company
          outside the United States typically are denominated in local
          currencies,  the results  of operations  of the  Company are
          expected to  continue to be affected by  changes in exchange
          rates  between  certain  foreign currencies  and  the United
          States Dollar.  There  can be no assurance that  the Company
          will not  experience currency fluctuation effects  in future
          periods, which could have an adverse impact on its business,
          results of operation or financial condition.  The operations
          and   financial  results   of  the   Company  also   may  be
          significantly  affected  by  other   international  factors,
          including changes  in governmental regulations or import and
          export  restrictions, and  foreign  economic  and  political
          conditions generally.

               The Company's ability to continue to sell products into
          Europe  is dependent  to a  large extent  on its  ability to
          maintain the important  ISO 9001/EN  4601 certification  and
          the CE marking  of conformity.  If the  Company were to lose
          such  certifications,  such  loss  would  have  a  material,
          adverse impact on international sales and profits.

               POSSIBLE VOLATILITY  OF STOCK PRICE.   The market price
          of  the Company's stock is,  and is expected  to continue to
          be,  subject  to  significant  fluctuations in  response  to
          variations  in quarterly  operating results,  trends  in the
          health  care  industry in  general  and  the medical  device
          industry in particular, and certain other factors beyond the
          control  of   the  Company.    In   addition,  broad  market
          fluctuations,  as  well  as general  economic  or  political
          conditions  and initiatives, may adversely impact the market
          price of  the Company's  stock, regardless of  the Company's
          operating performance.

               YEAR  2000 ISSUES.    The approaching  Year 2000  could
          result  in   challenges   related  to   computer   software,
          accounting  records,  and relationships  with  suppliers and
          customers.  Management of the  Company is studying Year 2000
          issues,  seeking to avoid such problems, but there can be no  
          assurance that such problems will not be encountered.


                                     PART II

          ITEM 5.   MARKET FOR REGISTRANT'S  COMMON EQUITY AND RELATED
                    STOCKHOLDER MATTERS

               The information required by  Item 5 of this Part  II is
          incorporated herein  by reference from  the Company's Annual
          Report.

          ITEM 6.  SELECTED CONSOLIDATED FINANCIAL DATA

               The information required by  Item 6 of this Part  II is
          incorporated by reference from the Company's Annual Report.

          ITEM 7.   MANAGEMENT'S DISCUSSION AND ANALYSIS  OF FINANCIAL
                    CONDITION AND RESULTS OF OPERATIONS

               The information required by  Item 7 of this Part  II is
          incorporated  herein by reference  from the Company's Annual
          Report.

          ITEM 8.   CONSOLIDATED     FINANCIAL      STATEMENTS     AND
                    SUPPLEMENTARY DATA

               The   Company's  consolidated  balance   sheets  as  of
          September  30, 1996  and 1995  and the  related consolidated
          statements  of  operations,  stockholders' equity  and  cash
          flows  for each  of  the three  years  in the  period  ended
          September 30, 1996 are incorporated herein by reference from
          the Company's Annual Report.

          ITEM 9.   CHANGES IN AND  DISAGREEMENTS WITH ACCOUNTANTS  ON
                    ACCOUNTING AND FINANCIAL DISCLOSURE

               There are no disagreements on accounting and  financial
          disclosure to be disclosed under this Item 9.


                                    PART III

          ITEM 10.  DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

               DIRECTORS

               The  information  required   by  Item  10  related   to
          Directors of the Company is incorporated herein by reference
          from the Proxy Statement.

               EXECUTIVE OFFICERS

               The   President,   Executive   Vice   President,   Vice
          Presidents, Secretary,  Treasurer,  and General  Counsel  of  
          Ballard Medical Products are elected annually at the regular
          meeting  of  the Board  of  Directors  following the  Annual
          Meeting of Shareholders  and serve at the  discretion of the
          Board   of  Directors.      There  is   no  arrangement   or
          understanding between any  executive officer  and any  other
          person pursuant to which he  was or is to be selected  as an
          officer.  The business background for at least the past five
          years of each executive officer is as follows:

          NAME AND AGE                  BACKGROUND

          Dale H. Ballard (75)          President,   Chief   Executive
                                        Officer, Chairman of the Board
                                        (1)

          Harold R. ("Butch")           Executive Vice President,
          Wolcott (51)                  General Manager (2)

          E. Martin Chamberlain (57)    Director,  Vice  President  of
                                        Regulatory  Affairs, Secretary
                                        (3)

          Daniel Burman (41)            Vice President of Sales (4)

          Bradford D. Bell (48)         Vice President of Marketing 
                                        and International Sales (5)

          Kenneth R. Sorenson (54)      Treasurer     and    Principal
                                        Financial Officer (6)

          Paul W. Hess (43)             Director, General Counsel (7)

          (1)  See Proxy Statement, p. 16.

          (2)  Mr. Wolcott was appointed by  the Board of Directors as
               Executive Vice President of Ballard in June,  1994.  He
               was  hired  by  the   Company  as  General  Manager  in
               December,  1992.   Prior  to  joining  Ballard, he  was
               employed by Pilot  Cardiovascular Systems, Inc.  in San
               Clemente,  California, from April, 1991 until December,
               1992, where  he worked  initially as Vice  President of
               Operations and later as  Chief Operating Officer.  From
               April,  1990  to  April,  1991,  Mr.  Wolcott  provided
               consulting   services   to   various   medical   device
               companies.   From January, 1987 until  April, 1990, Mr.
               Wolcott worked for  Catheter Technology Corporation  of
               Salt   Lake   City,   Utah,   as  Vice   President   of
               Manufacturing.

          (3)  See Proxy Statement, p. 17.

          (4)  Mr. Burman was appointed Vice President of Sales on May
               7, 1997.  He served as Ballard's National Sales Manager
               from 1994 to 1997.   From 1990 through 1993,  he served
               as  one  of Ballard's  Division  Managers.   He  joined  
               Ballard as a sales representative in 1986 in New  York.

          (5)  Mr.  Bell was  appointed  Vice President  of Sales  and
               Marketing  on August 1, 1994.  He served as Director of
               Marketing for  Ballard since  October, 1991.   Prior to
               coming to work  for Ballard, Mr.  Bell worked for  Bard
               Access Systems (formerly  named Davol/Cath Tech, Inc.),
               where he served as Director of Marketing  from the fall
               of 1988 until October, 1991.  

          (6)  Mr.  Sorenson joined the Company in July, 1985.  He has
               worked   in  the  Company's  Finance  Department  since
               joining  the  Company.    He became  Treasurer  of  the
               Company in August, 1985.  Mr. Sorenson is a graduate of
               Brigham Young University in Accounting.

          (7)  See Proxy Statement, p. 18.

          ITEMS 11, 12, and 13.

               The information required by Items 11, 12 and 13 of this
          Part III is incorporated herein by reference from  the Proxy
          Statement.

                                     PART IV

          ITEM 14.  EXHIBITS,   CONSOLIDATED   FINANCIAL   STATEMENTS,
                    CONSOLIDATED  FINANCIAL  STATEMENT SCHEDULES,  AND
                    REPORTS ON FORM 8-K

               (a) DOCUMENTS FILED AS PART OF REPORT

                    1.   CONSOLIDATED FINANCIAL
                         STATEMENTS

               The  following  are  included  in  the  Annual   Report
          incorporated  by  reference  into Parts  I  and  II  of this
          report:

                    Independent Auditor's Report,  dated November  13,
                    1997;

                    Consolidated  Balance Sheets  as of  September 30,
                    1997 and 1996;

                    Consolidated  Statements  of  Operations  for  the
                    Years Ended September 30, 1997, 1996, and 1995;

                    Consolidated  Statements  of Stockholders'  Equity
                    for the Years Ended  September 30, 1997, 1996, and
                    1995;

                    Consolidated  Statements  of  Cash  Flows  for the
                    Years Ended September 30, 1997, 1996 and 1995;  

                    Notes to Consolidated Financial Statements.
           
                    2.   CONSOLIDATED FINANCIAL STATEMENT SCHEDULES

               The following are included in this report:

                    Independent  Auditors'  Report dated  November 13,
                    1997;

                    Supplemental  Schedule II - Valuation Accounts for
                    the Three Years Ended September 30, 1997;

                    Other   schedules   required  by   Rule   5.04  of
                    Regulation S-X are omitted because of  the absence
                    of the conditions under which they are required or
                    because  the required  information is  included in
                    the consolidated financial  statements or  related
                    notes.

                    3.   EXHIBITS

               See   "Ballard  Medical  Products  Index  to  Exhibits"
          attached to this report.

               (b)  REPORTS ON FORM 8-K

               No  reports on Form  8-K were filed  during the quarter
          ended September 30, 1997.

               (c)  EXHIBITS

               See  "Ballard  Medical   Products  Index  to  Exhibits"
          attached to this report.

               (d)  SEPARATE FINANCIAL STATEMENT
                    SCHEDULES

               Not applicable.

                                   SIGNATURES

               Pursuant  to the requirements of Section 13 or 15(d) of
          the Securities Exchange Act of 1934, the Registrant has duly
          caused  this  report  to be  signed  on  its  behalf by  the
          undersigned thereunto duly authorized.

          Date:  December 15, 1997      BALLARD MEDICAL PRODUCTS

                                        By:  Dale H. Ballard
                                             President, Director
                                             (Principal Executive
                                             Officer)

               Pursuant to the requirements of the Securities Exchange 
          Act  of 1934,  this  report has  been  signed below  by  the
          following  persons on  behalf of  the Registrant and  in the
          capacities and on the dates indicated.

          Date:  December 15, 1997      By:  Dale H. Ballard
                                             Director

          Date:  December 15, 1997      By:  E. Martin Chamberlain
                                             Director

          Date:  December 15, 1997      By:  Dale H. Ballard, Jr.
                                             Director

          Date:  December 15, 1997      By:  Paul W. Hess
                                             Director

          Date:  December 15, 1997      By:  Kenneth R. Sorenson
                                             Treasurer (Principal
                                             Financial Officer)

          INDEPENDENT AUDITORS' REPORT

          To  the  Board  of  Directors 
          and  Stockholders  of  
          Ballard Medical Products:

               We  have audited the  consolidated financial statements
          of Ballard Medical Products and subsidiaries as of September
          30, 1997  and 1996, and for  each of the three  years in the
          period ended September 30, 1997,  and have issued our report
          thereon dated November 13, 1997; such consolidated financial
          statements  and  report are  included  in  your 1997  Annual
          Report  to  Stockholders  and  are  incorporated  herein  by
          reference.    Our  audits  also  included  the  consolidated
          financial  statement schedules  of Ballard  Medical Products
          and  subsidiaries, listed  in Item  14.   These consolidated
          financial statement schedules are the responsibility of  the
          Company's management.   Our responsibility is  to express an
          opinion  based  on  our  audits.     In  our  opinion,  such
          consolidated financial statement schedules,  when considered
          in relation to the  basic consolidated financial  statements
          taken as a  whole, present fairly in all  material respects,
          the information set forth therein.

                                                 Deloitte & Touche LLP
                                                  Salt Lake City, Utah
                                                     November 13, 1997

          <TABLE>
          <CAPTION>

          SUPPLEMENTAL SCHEDULE II
          BALLARD MEDICAL PRODUCTS
          VALUATION ACCOUNTS
          FOR THE THREE YEARS IN THE PERIOD 
          ENDED SEPTEMBER 30, 1997  

                             BALANCE AT    ADDITION               BALANCE AT
                              BEGINNING          TO   CHARGED TO      END OF
                                OF YEAR   ALLOWANCE        COSTS        YEAR

          <S>                  <C>       <C>          <C>         <C> 

          ALLOWANCE FOR
          DOUBTFUL ACCOUNTS:

              1997             $182,000  $1,216,000   $(560,000)  $(838,000)

              1996             $125,000     $57,000         NONE    $182,000

              1995             $200,000        NONE    $(75,000)    $125,000

          ALLOWANCE FOR
          SALES RETURNS:

              1997             $805,000    $965,000   $(110,000)  $1,660,000

              1996             $500,000    $305,000         NONE    $805,000

              1995             $200,000    $300,000         NONE    $500,000

           ALLOWANCE FOR
           INVENTORY
           OBSOLESCENCE:

              1997             $652,917    $601,860   $(137,829)  $1,116,948

              1996             $130,453    $522,464         NONE    $652,917

              1995                 NONE    $130,453         NONE    $130,453
</TABLE>

                            BALLARD MEDICAL PRODUCTS

                                Index to Exhibits


           EXHIBIT     EXHIBIT DESCRIPTION   SEQUENTIALLY NUMBERED PAGE
           NO.

            3.1        Restated Certificate  Incorporated herein by
                       of Incorporation,     reference to Exhibit 3.1 to
                       dated June 18, 1987   Form 10-K, filed December
                                             29, 1989.

            3.2        July 10, 1991         Incorporated herein by
                       Articles of           reference to Exhibit 4.2 to
                       Amendment to          the Registration Statement
                       Articles of           on Form S-3, filed November
                       Incorporation         13, 1991, Registration No.
                                             33-43910.  

            3.3        September 20, 1993    Incorporated herein by
                       Articles of           reference to Exhibit 3.3 to
                       Amendment to          Form 10-K filed December
                       Articles of           16, 1993.
                       Incorporation

            3.4        Amended and Restated  Incorporated herein by
                       Bylaws, dated         reference to Exhibit 3.3 to
                       October 12, 1992      Form 10-K, filed December
                                             24, 1992.

            4.1        See Exhibits 3.1,
                       3.2, 3.3, 10.1,
                       10.2, 10.3, 10.4,
                       10.5, 10.6, 10.7,
                       10.8 and 10.9

            9          None

           10.1        Material Contract:    Incorporated herein by
                       1988 Incentive Stock  reference to the
                       Option Plan           Registration Statement on
                                             Form S-8, filed November
                                             18, 1988, Registration No.
                                             33-25628.

           10.2        Material Contract:    Incorporated herein by
                       1990 Incentive Stock  reference to the
                       Option Plan           Registration Statement on
                                             Form S-8, filed September
                                             17, 1990, Registration No.
                                             33-36851.

           10.3        Material Contract:    Incorporated herein by
                       1991 Incentive Stock  reference to Exhibit 4.2 to
                       Option Plan           Registration Statement on
                                             Form S-8, filed July 10,
                                             1991, Registration No. 33-
                                             41720.

           10.4        Material Contract:    Incorporated herein by
                       1992 Incentive Stock  reference to Exhibit 4.3 to
                       Option Plan           Registration Statement on
                                             Form S-8, filed with Post-
                                             Effective Amendment No. 1
                                             on April 9, 1993,
                                             Registration No. 33-56302.  

           10.5        Material Contract:    Incorporated herein by
                       Amended and Restated  reference to Exhibit 4.5 to
                       1993 Incentive Stock  Registration Statement on
                       Option Plan           Form S-8, filed December
                                             20, 1993, Registration No.
                                             33-73194.

           10.6        Material Contract:    Incorporated herein by
                       1994 Incentive Stock  reference to Exhibit 10.8
                       Option Plan           to Form 10-K filed December
                                             15, 1994. 

           10.7        Material Contract:    Incorporated herein by
                       1995 Incentive Stock  reference to Exhibit 10.9
                       Option Plan           to Form 10-K filed December 
                                             8, 1995. 

           10.8        Material Contract:    Incorporated herein by
                       1996 Incentive Stock  reference to Exhibit 10.10
                       Option Plan           to Form 10-K filed December
                                             9, 1996

           10.9        Material Contract:    p.
                       1997 Incentive Stock
                       Option Plan

           10.10       Material Contract:    Incorporated herein by
                       Agreement of          reference to Exhibit 19 to
                       Settlement dated      Form 10-Q, filed May 15,
                       March 1, 1990, with   1990.
                       Smiths Industries
                       Medical Systems,
                       Inc. and Smiths
                       Industries PLC

           10.11       Material Contract:    Incorporated herein by
                       Agreement dated       reference to Exhibit 10.21
                       effective October 1,  to Form 10-K, filed
                       1993 between Ballard  December 16, 1993.
                       Medical Products and
                       H. Earl Wright and
                       The Wright Foamer
                       Co.

           10.12       Material Contract:    Incorporated herein by
                       Stock Purchase        reference to Exhibit 99.1
                       Agreement (with       to Form 8-K, filed December
                       various "Sellers"     23, 1996.
                       named therein)  

           10.13       Material Contract:    Incorporated herein by
                       Stock Purchase        reference to Exhibit 99.2
                       Agreement (with SO-   to Form 8-K, filed December
                       CAL PARTNERS, L.P.,   23, 1996.
                       as "Seller")

           10.14       Material Contract:    Incorporated herein by
                       Merger Agreement      reference to Exhibit 99.3
                                             to Form 8-K, filed December
                                             23, 1996.

           11          Computation of        p.
                       Income Per Common
                       Share and Common
                       Equivalent Share

           12          Not Applicable

           13          Ballard Medical       p.
                       Products 1997 Annual
                       Report for the year
                       ended September 30,
                       1997

           16          Not Applicable

           18          Not Applicable

           21          Subsidiaries of       p.
                       Ballard Medical
                       Products

           22          Not Applicable

           23          Not Applicable

           24          Not Applicable

           25          Not Applicable

           26          Not Applicable

           27          Financial Data        p.
                       Schedule

           28          Not Applicable